 |
49 Diseases |  |
53 Trials |
|
53 Trials |  |
326 News |  |
| «12345 |
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer (clinicaltrials.gov) - Feb 24, 2014
P2, N=140, Recruiting, Sponsor: Fudan University
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion, Combination therapy: Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=39, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion, Metastases: Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P4 trial, Metastases: Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases (clinicaltrials.gov) - Oct 7, 2013
P4, N=320, Active, not recruiting, Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
- ||| Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment closed, Metastases: Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases (clinicaltrials.gov) - Oct 6, 2013
P4, N=320, Active, not recruiting, Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
Not yet recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial: A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer (clinicaltrials.gov) - Apr 17, 2013
P2, N=100, Active, not recruiting, Sponsor: Hebei Tumor Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Jan 20, 2013
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial: A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer (clinicaltrials.gov) - Nov 20, 2012
P2, N=108, Recruiting, Sponsor: The First People's Hospital of Lianyungang
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic (clinicaltrials.gov) - Oct 9, 2012
P2, N=80, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion: Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura (clinicaltrials.gov) - Jul 16, 2012
P3, N=256, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial completion: Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed (clinicaltrials.gov) - Jul 16, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Tomudex (raltitrexed) / Pfizer, AstraZeneca
New P2 trial, Metastases: BEVATOMOX: 2nd-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 13, 2012
P2, N=124, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
- Avastin (bevacizumab) / Roche
New P2 trial: Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer (clinicaltrials.gov) - Nov 27, 2011
P2, N=46, Active, not recruiting, Sponsor: National Cancer Institute, Naples